<h3>认识您的 ETF 人工智能分析师</h3>
<ul>
<li>了解 TipRanks 的_ETF_人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，查看 <strong>_ETF_人工智能分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>Telomir Pharmaceuticals, Inc.（(TELO)）最新公告已发布。</p>
<p>Telomir Pharmaceuticals, Inc.宣布了新的临床前数据，表明其研究化合物 Telomir-1 在降低人类角质形成细胞内铁水平方面比 FDA 批准的铁螯合剂去铁胺（DFO）更有效。这一发现突显了 Telomir-1 在调节铁水平方面的潜力，这对于应对氧化压力和表观遗传调控至关重要，这些因素与衰老和各种疾病相关。研究结果表明，Telomir-1 可能在推进金属离子稳态及其对细胞健康影响的研究中发挥重要作用。</p>
<p>(TELO) 股票的最新分析师评级为买入，目标价为 15.00 美元。要查看 Telomir Pharmaceuticals, Inc.股票的完整分析师预测列表，请参见 TELO 股票预测页面。</p>
<p><strong>关于 Telomir Pharmaceuticals, Inc.的更多信息</strong></p>
<p>Telomir Pharmaceuticals, Inc.在制药行业运营，专注于调节金属离子平衡和氧化压力的化合物开发。该公司从事临床前研究，特别是在衰老和退行性疾病领域，市场重点是开发解决细胞健康和表观遗传控制的创新治疗方案。</p>
<p><strong>平均交易量：</strong> 3,000,482</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 4710 万美元</p>

TELO

<p>Telomir Pharmaceuticals, Inc. (TELO) 发布了令人鼓舞的临床前数据，显示其化合物 Telomir-1 能有效降低人类角质形成细胞内的铁水平，优于 FDA 批准的铁螯合剂去铁胺。这一发现表明 Telomir-1 在应对氧化压力和表观遗传调控方面的潜力，这与衰老和疾病相关。分析师将 TELO 股票评级为买入，目标价为 15.00 美元。该公司专注于开发金属离子平衡和细胞健康的治疗方案，目前市值为 4710 万美元</p>

<h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF 人工智能分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的_ETF_人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，查看 <strong>_ETF_人工智能分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).</p>
<div class="lb-trans"><p>Telomir Pharmaceuticals, Inc.（(TELO)）最新公告已发布。</p>
</div><p>Telomir Pharmaceuticals, Inc. has announced new preclinical data indicating that its investigational compound, Telomir-1, significantly reduces intracellular iron levels in human keratinocytes more effectively than the FDA-approved iron chelator Deferoxamine (DFO). This discovery highlights Telomir-1’s potential in modulating iron levels, which is crucial for addressing oxidative stress and epigenetic regulation, factors linked to aging and various diseases. The findings suggest that Telomir-1 could play a significant role in advancing research on metal-ion homeostasis and its implications for cellular health.</p>
<div class="lb-trans"><p>Telomir Pharmaceuticals, Inc.宣布了新的临床前数据，表明其研究化合物 Telomir-1 在降低人类角质形成细胞内铁水平方面比 FDA 批准的铁螯合剂去铁胺（DFO）更有效。这一发现突显了 Telomir-1 在调节铁水平方面的潜力，这对于应对氧化压力和表观遗传调控至关重要，这些因素与衰老和各种疾病相关。研究结果表明，Telomir-1 可能在推进金属离子稳态及其对细胞健康影响的研究中发挥重要作用。</p>
</div><p>The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.</p>
<div class="lb-trans"><p>(TELO) 股票的最新分析师评级为买入，目标价为 15.00 美元。要查看 Telomir Pharmaceuticals, Inc.股票的完整分析师预测列表，请参见 TELO 股票预测页面。</p>
</div><p><strong>More about Telomir Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Telomir Pharmaceuticals, Inc.的更多信息</strong></p>
</div><p>Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of compounds that modulate metal-ion balance and oxidative stress. The company is engaged in pre-clinical research, particularly in the areas of aging and degenerative diseases, with a market focus on innovative treatments that address cellular health and epigenetic control.</p>
<div class="lb-trans"><p>Telomir Pharmaceuticals, Inc.在制药行业运营，专注于调节金属离子平衡和氧化压力的化合物开发。该公司从事临床前研究，特别是在衰老和退行性疾病领域，市场重点是开发解决细胞健康和表观遗传控制的创新治疗方案。</p>
</div><p><strong>Average Trading Volume:</strong> 3,000,482</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 3,000,482</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> $47.1M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 4710 万美元</p>
</div>

Telomir Pharmaceuticals 公布了有前景的临床前数据